Updated
Updated · Bloomberg · Jul 7Vertex Buys Crinetics for $10 Billion, Paying 102% Premium to Expand Endocrinology
3 articles · Updated · Bloomberg · Jul 7Summary
- Vertex agreed to acquire Crinetics in an all-cash deal worth $10 billion, marking the largest acquisition in Vertex’s history.
- The offer values Crinetics at $85 a share, a 102% premium to Monday’s close, underscoring Vertex’s push into endocrinology.
- The takeover gives Vertex a broader foothold in a new therapeutic area as it looks to expand beyond its existing portfolio.
- The deal surpasses Vertex’s previous biggest acquisition — the $4.4 billion purchase of Alpine Immune Sciences in 2024.
Insights
After insiders sold millions in stock, is Vertex's $10 billion bet on Crinetics a massive overpayment? Will this mega-deal create breakthrough rare disease treatments or just higher costs for patients?